Synthesis and biological properties of new constrained CCK-B antagonists: Discrimination of two affinity states of the CCK-B receptor on transfected CHO cells

Journal of Medicinal Chemistry

Volumn 40, Issue 24, 1997, Pages 3947-3956

  Bellier, Bruno ^a   McCort Tranchepain, Isabelle ^a   Ducos, Bertrand ^a   Danascimento, Sophie ^a   Meudal, Hervé ^a   Noble, Florence ^a   Garbay, Christiane ^a   Roques, Bernard P ^a  

^a FACULTÉ DES SCIENCES PHARMACEUTIQUES ET BIOLOGIQUES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,3 DIHYDRO 1 METHYL 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL) 3 (3 METHYLPHENYL)UREA; 4 [[2 [2 [[(2 ADAMANTYLOXY)CARBONYL]AMINO] 3 (1H INDOL 3 YL) 2 METHYLPROPIONAMIDO] 1 PHENYLETHYL]AMINO] 4 OXOBUTYRIC ACID MEGLUMINE; CHOLECYSTOKININ B RECEPTOR; CHOLECYSTOKININ B RECEPTOR ANTAGONIST; INOSITOL PHOSPHATE; RB 210; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN MEMBRANE; CHO CELL; CONTROLLED STUDY; CYCLIZATION; DRUG CONFORMATION; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; GUINEA PIG; NONHUMAN; PANCREAS; RECEPTOR AFFINITY; STRUCTURE ACTIVITY RELATION;

ADAMANTANE; ANIMALS; CHO CELLS; CRICETINAE; DIPEPTIDES; GUINEA PIGS; KINETICS; MAGNETIC RESONANCE SPECTROSCOPY; PEPTOIDS; PROLINE; PROTEIN CONFORMATION; RATS; RECEPTOR, CHOLECYSTOKININ A; RECEPTOR, CHOLECYSTOKININ B; RECEPTORS, CHOLECYSTOKININ; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY; TRANSFECTION;

EID: 0030831366     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm970439a     Document Type: Article

References (41)

1. Reviewed in (a) Crawley, J. N.; Corwin, R. L. Biological actions of cholecystokinin. Peptides 1994, 15, 731-755. (b) Harro, J.; Vasar, E.; Bradwejn, F. CCK in animal and human research on anxiety. Trends Pharmacol. Sci. 1993, 14, 244-249. (c) Daugé, V.; Roques, B. P. Opioid and CCK system in anxiety and reward. In Cholecystokinin and Anxiety. From Neuron to Behavior; Bradwejn, J., Vasar, E., Eds.; R. G. Landes Co.: Austin, TX, 1995.
2. Reviewed in (a) Crawley, J. N.; Corwin, R. L. Biological actions of cholecystokinin. Peptides 1994, 15, 731-755. (b) Harro, J.; Vasar, E.; Bradwejn, F. CCK in animal and human research on anxiety. Trends Pharmacol. Sci. 1993, 14, 244-249. (c) Daugé, V.; Roques, B. P. Opioid and CCK system in anxiety and reward. In Cholecystokinin and Anxiety. From Neuron to Behavior; Bradwejn, J., Vasar, E., Eds.; R. G. Landes Co.: Austin, TX, 1995.
3. Reviewed in (a) Crawley, J. N.; Corwin, R. L. Biological actions of cholecystokinin. Peptides 1994, 15, 731-755. (b) Harro, J.; Vasar, E.; Bradwejn, F. CCK in animal and human research on anxiety. Trends Pharmacol. Sci. 1993, 14, 244-249. (c) Daugé, V.; Roques, B. P. Opioid and CCK system in anxiety and reward. In Cholecystokinin and Anxiety. From Neuron to Behavior; Bradwejn, J., Vasar, E., Eds.; R. G. Landes Co.: Austin, TX, 1995.
4. Evans, B. E.; Bock, M. G.; Rittle, K. E.; DiPardo, R. M.; Whitter, W. L.; Verber, D. F.; Anderson, P. S.; Freidinger, R. M. Design of potent orally effective nonpeptidal antagonists of the peptide hormone cholecystokinin. Proc. Natl. Acad. Sci. U.S.A. 1986, 83, 4918-4922.
5. Paris, P. L.; Komisaruk, B. R.; Watkins, L. R.; Mayer, D. J. Evidence for the neuropeptide cholecystokinin as an antagonist of opiate analgesia. Science 1983, 219, 310-312.
6. Maldonado, R.; Derrien, M.; Noble, F.; Roques, B. P. Association of the peptidase inhibitor RB 101 and a selective CCK-B antagonist strongly enhances antinociceptive responses. Neural. Rep. 1993, 4, 947-950.
7. Derrien, M.; Durieux, C.; Roques, B. P. Antidepressant-like effects of CCK-B antagonists in mice: antagonism by naltrindole. Br. J. Pharmacol. 1994, 111, 956-960.
8. Bock, M. G.; DiPardo, R. M.; Evans, B. E.; Rittle, K. E.; Whitter, W. L.; Veber, D. F.; Anderson, P. S.; Freidinger, R. M. Benzodiazepine gastrin and brain cholecystokinin receptor ligands. J. Med. Chem. 1989, 32, 2, 13-16.
9. Harper, E. A.; Roberts, S. P.; Shankley, N. R.; Black, J. W. Analysis of variation in L-365,260 competition curves in radioligand binding assays. Br. J. Pharmacol. 1996, 118, 1717-1726.
10. Leinre, S.; Schoneberg, T.; Meyer, R.; Martin, H.; Kaufmann, R. Pharmacological characterization of CCK-B receptors in human brain: no evidence for receptors heterogeneity. Neurosci. Lett. 1996, 277, 45-49.
11. Blommaert, A. G. S.; Weng, J.-H.; Dorville, A.; McCort, I.; Ducos, B.; Durieux, C.; Roques, B. P. Cholecystokinin peptidomimetics as selective CCK-B antagonists: Design, synthesis, and in vitro and in vivo biochemical properties. J. Med. Chem. 1993, 36, 2868-2877.
12. Horwell, D. C.; Hughes, J.; Hunter, J. C.; Pritchard, M. C.; Richardson, R. S.; Roberts, E.; Woodruff, G. N. Rationally designed "dipeptoid" analogues of CCK, α-Methyltryptophan derivatives as highly selective and orally active gastrin and CCK-B antagonists with potent anxiolytic properties. J. Med. Chem. 1991, 34, 4, 404-414.
13. Durieux, C.; Derrien, M.; Maldonado, R.; Valverde, O.; Blommaert, A.; Fournié-Zaluski, M. C.; Roques, B. P. CCK-B antagonists exhibit antidepressant-like effects and potentiate endogenous enkephalin analgesia. Correlation with in vivo binding affinities and brain penetration. Ann. N.Y. Acad. Sci. 1994, 713 (508), 355-357.
14. A receptor agonist. Eur. J. Pharmacol. 1993, 242, 105-108.
15. (b) Ding, X.-Q.; Chen, D.; Hakanson, R. Cholecystokinin-B/gastrin receptor ligands of the dipeptoids series act as agonists on histidine decarboxylase in rat stomach anterochromaffin-like cells. Pharmacol. Toxicol. 1995, 76 (Suppl. IV), 81.
16. Fincham, C. I.; Horwell, D. C.; Ratcliffe, G. S.; Rees, D. C. The use of a proline ring as a conformational restraint in CCK-B receptor "dipeptoids". BioMed. Chem. Lett. 1992, 2, 403-406.
17. (a) Didier, E.; Horwell, D. C.; Pritchard, M. C. Synthesis and CCK-B binding affinities of cyclic analogues of the potent and selective CCK-B antagonist CI-988. Tetrahedron 1992, 48, 8471-8490.
18. (b) Bolton, G. L.; Roth, B. D.; Trivedi, B. K. Synthesis of conformationally constrained macrocyclic analogues of the potent and selective CCK-B antagonist CI-988, Tetrahedron 1993, 49, 525-536.
19. (c) Fincham, C. I.; Higginbottom, M.; Hill, D. R.; Horwell, D. C.; O'Toole, J. C.; Ratcliffe, G. S.; Rees, D. C.; Roberts, E. Amide bond replacements incorporated into CCK-B selective "dipeptoids". J. Med. Chem. 1992, 35, 1472-1484.
20. Higginbottom, M.; Hill, D. R.; Horwell, D. C.; Mostafai, E.; Suman-Chauhan, N.; Roberts, E. Conformationally restricted analogues of the potent CCK-B antagonist CI-988. BioMed. Chem. 1993, 1, 209-217.
21. Blommaert, A. G. S.; Dhotel, H.; Ducos, B.; Durieux, C.; Goudreau, N.; Bado, A.; Garbay, C.; Roques, B. P. Structure-based design of new constrained cyclic agonists of the cholecystokinin CCK-B receptor. J. Med. Chem. 1997, 40, 647-658.
22. (a) Baer, E.; Stedman, R. J. Derivatives of hydroxy-L-proline. Can. J. Biochem. Physiol. 1959, 37, 583-587.
23. (b) Wang, S.-S.; Gisin, B. F.; Winter, D. P.; Makofske, R.; Kulesha, I. D.; Tzougraki, C.; Meienhofer, J. Facile synthesis of amino acid and peptide esters under mild conditions via cesium salts. J. Org. Chem. 1977, 42, 1286-1290.
24. (a) Patchett, A. A.; Witkop, B. Studies on hydroxyproline. J. Am. Chem. Soc. 1957, 79, 185-192.
25. (b) Krapcho, J.; Turk, C.; Cushman, D. W.; Powell, J. R.; DeForrest, J. M.; Spitzmiller, E. R.; Karanewsky, D. S.; Duggan, M.; Rovnyak, G.; Schwartz, J.; Natarajan, S.; Godfrey, J. D.; Ryono, D. E.; Neubeck, R.; Atwal, K-S.; Petrillo, E. W., Jr. Angiotensin-converting enzyme inhibitors. Mercaptan, carboxyalkyl dipeptide, and phosphinic acid inhibitors incorporating 4-substituted prolines. J. Med. Chem. 1988, 37, 1148-1160.
26. Mitsunobu, O. The use of diethyl azodicarboxylate and triphenylphosphine in synthesis and transformation of natural products. Synthesis 1981, 1-28.
27. Mashimo, K.; Sato, Y. Synthesis of isojmaline. Tetrahedron 1970, 26, 803-812.
28. Anantharamaiah, G. M.; Roeske, R. W. Resolution of α-methyl amino esters by chymotrypsin. Tetrahedron Lett. 1982, 23, 3335-3336.
29. Roques, B. P. Peptidomimetics as receptors agonists or peptidase inhibitors: A structural approach in the field of enkephalin, ANP and CCK. Biopolymers 1992, 32, 407-410.
30. (a) Kopin, A. S.; McBride, E. W.; Quinn, S. M.; Kolakowski, L. F.; Beinborn, M. The role of the cholecystokinin-B/gastrin receptor transmembrane domains in determining affinity for subtype-selective liganda. J. Biol. Chem. 1995, 270, 5019-5023.
31. 381 in the seventh transmembrane domain of the CCK-B receptor is essential for B versus A antagonists selectivity. Eur. J. Pharmacol. (Mol. Sect.) 1995, 296, 97-106.
32. Morley, J. E.; Levine, A. S.; Bartness, T. J.; Niziesky, S. E.; Shaw, M. J.; Hughes, J. J. Species differences in the response to cholecystokinin. Ann. N.Y. Acad. Sci. 1985, 488, 413-416.
33. Durieux, C.; Coppey, M.; Zajac, J. M.; Roques, B. P. Occurrence of two cholecystokinin binding sites in guinea pig brain cortex. Biochem. Biophys. Res. Commun. 1986, 137, 1167-1173.
34. Derrien, M.; McCort-Tranchepain, I.; Ducos, B.; Roques, B. P.; Durieux, C. Heterogeneity of CCK-B receptors involved in animal models of anxiety. Pharmacol. Biochem. Behav. 1994, 49, 133-141.
35. 26-33): evidence for receptor heterogeneity. J. Pharmacol. Exp. Ther. 1990, 255, 1278-1286.
36. Huang, S.; Fortune, K. P.; Wank, S. A.; Kopin, A. S.; Gardner, J. D. Multiple affinity states of different cholecystokinin receptors. J. Biol. Chem. 1994, 269, 26121-26126.
37. Ito, M.; Matsui, T.; Taniguchi, T.; Tsukamoto, T.; Murayama, T.; Noriyuki, A.; Nakata, H.; Chiba, T.; Chihara, K. Functional characterization of a human brain cholecystokinin-B receptor. J. Biol. Chem. 1993, 268, 18800-18805.
38. Lee, Y. M.; Beinborn, M.; McBride, E. W.; Lu, M.; Kolakowski, L. F.; Kopin, A. S. The human brain cholecystokinin-B/gastrin receptor. J. Biol. Chem. 1993, 268, 8164-8169.
39. 3H]SNF 8702. Mol. Pharmacol. 1992, 47, 1089-1095.
40. Chen, C.; Okayama, H. High efficiency transformation of mammalian cells by plasmid DNA. Mol. Cell Biol. 1987, 7, 2745-2752.
41. Berridge, M. J.; Dawson, R. M. C.; Downes, C. P.; Heslop, J. P.; Orvine, R. F. Changes in the levels of inositol phosphates after agonist-dependent hydrolysis of membrane phosphoinosides. Biochem, J. 1983, 272, 473-782.